PhRMA Releases 2014 Cancer Report Detailing Nearly 800 New Medicines
The Pharmaceutical Research and Manufacturers of America released their 2014 Cancer Report that highlights the biopharmaceutical companies developing new medicines and vaccines used for the treatment of cancer.
Cancer accounts for one in every four deaths in the United States, with the number of individuals developing cancer increasing every year. In 2001, there were 9.8 million cases of cancer, and in 2012, there were 13.7 million reported cases, yet deaths have decreased by 20% since the 1990s, according to the American Cancer Society. On Oct. 6, 2014, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a new
that details the steps biopharmaceutical research companies in the US are taking to develop nearly 800 new medicines and vaccines for cancer.
"Continued research has expanded our knowledge of how cancer develops and how to target medicines for specific cancer types, which has resulted in more effective therapies for patients,” said PhRMA President and CEO John J. Castellani, in a press release.
Biopharmaceutical research companies are working together with academic medical centers, government, and non-profit organizations to continue to increase the number of new therapies. The report explains that there are over 200 unique diseases and 771 medicines and vaccines in clinical trials or awaiting FDA review. Of these treatments, 98 are for lung cancer, 87 for leukemia, 78 for lymphoma, 73 for breast cancer, 56 for skin cancer, and 48 for ovarian cancer.
Source: PhRMA
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
